Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Oncocyte Corp (Nasdaq: OCX) has announced its participation in BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference taking place on February 11-12, 2025, in Snowbird, Utah. CEO Josh Riggs and CFO Andrea James will represent the diagnostics technology company at the event, where they will conduct one-on-one meetings with potential investors.
Interested investors attending the conference are encouraged to contact BTIG directly to schedule meetings with Oncocyte's leadership team.
Oncocyte Corp (Nasdaq: OCX) ha annunciato la sua partecipazione alla Conferenza MedTech, Salute Digitale, Scienze della Vita e Strumenti Diagnostici di BTIG, che si svolgerà dal 11 al 12 febbraio 2025 a Snowbird, Utah. Il CEO Josh Riggs e il CFO Andrea James rappresenteranno l'azienda tecnologica di diagnostica all'evento, dove condurranno incontri individuali con potenziali investitori.
Gli investitori interessati a partecipare alla conferenza sono invitati a contattare direttamente BTIG per programmare incontri con il team dirigenziale di Oncocyte.
Oncocyte Corp (Nasdaq: OCX) ha anunciado su participación en la Conferencia de MedTech, Salud Digital, Ciencia de la Vida y Herramientas Diagnósticas de BTIG, que se llevará a cabo del 11 al 12 de febrero de 2025 en Snowbird, Utah. El CEO Josh Riggs y la CFO Andrea James representarán a la empresa de tecnología de diagnóstico en el evento, donde realizarán reuniones uno a uno con posibles inversores.
Se anima a los inversores interesados en asistir a la conferencia a ponerse en contacto directamente con BTIG para programar reuniones con el equipo directivo de Oncocyte.
Oncocyte Corp (Nasdaq: OCX)는 2025년 2월 11일부터 12일까지 유타주 스노우버드에서 개최되는 BTIG의 MedTech, 디지털 헬스, 생명 과학 및 진단 도구 컨퍼런스에 참여한다고 발표했습니다. CEO 조시 리그스와 CFO 안드레아 제임스는 이 이벤트에서 진단 기술 회사를 대표하여 잠재 투자자들과 일대일 회의를 진행할 예정입니다.
컨퍼런스에 참석할 예정인 관심 있는 투자자들은 Oncocyte의 경영 팀과의 미팅을 예약하기 위해 BTIG에 직접 연락하시기 바랍니다.
Oncocyte Corp (Nasdaq: OCX) a annoncé sa participation à la Conférence MedTech, Santé Numérique, Sciences de la Vie et Outils Diagnostiques de BTIG, qui se tiendra du 11 au 12 février 2025 à Snowbird, Utah. Le PDG Josh Riggs et la CFO Andrea James représenteront l'entreprise de technologie diagnostique lors de cet événement, où ils mèneront des réunions en tête-à-tête avec des investisseurs potentiels.
Les investisseurs intéressés à assister à la conférence sont encouragés à contacter BTIG directement pour planifier des réunions avec l'équipe dirigeante d'Oncocyte.
Oncocyte Corp (Nasdaq: OCX) hat seine Teilnahme an der BTIG-Konferenz für MedTech, digitale Gesundheit, Lebenswissenschaften und Diagnosetools, die vom 11. bis 12. Februar 2025 in Snowbird, Utah, stattfindet, bekannt gegeben. CEO Josh Riggs und CFO Andrea James werden das Diagnosetechnologieunternehmen auf der Veranstaltung vertreten, wo sie persönliche Gespräche mit potenziellen Investoren führen werden.
Interessierte Investoren, die an der Konferenz teilnehmen, werden ermutigt, BTIG direkt zu kontaktieren, um Meetings mit dem Führungsteam von Oncocyte zu planen.
- None.
- None.
February 11-12, 2025, Snowbird, Utah
IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. Oncocyte will host one-on-one meetings with interested investors.
Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to schedule.
Event: BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference 2025
Dates: February 11-12, 2025
Location: Snowbird, Utah, USA
About Oncocyte
Oncocyte is a leading diagnostics technology company. The company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:
VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/
GraftAssure™ - https://oncocyte.com/graftassure/
DetermaIO™ - https://oncocyte.com/determa-io/
DetermaCNI™ - https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com
FAQ
When and where is Oncocyte (OCX) participating in the BTIG MedTech Conference 2025?
Who will represent Oncocyte (OCX) at the BTIG MedTech Conference 2025?
How can investors meet with Oncocyte (OCX) management at the BTIG Conference?
What type of meetings will Oncocyte (OCX) conduct at the BTIG Conference 2025?
